In a report released today, Matthew Keller from H.C. Wainwright reiterated a Buy rating on Gyre Therapeutics, with a price target of $18.00.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Matthew Keller has given his Buy rating due to a combination of factors that highlight Gyre Therapeutics’ strategic advancements and financial performance. The company’s revenue has shown a significant year-over-year increase, driven by the growth of key products such as ETUARY, Etorel, and Contiva. This positive revenue trend underscores the strength of Gyre’s commercial portfolio.
Additionally, Gyre Therapeutics is making notable progress in its clinical pipeline, particularly with the completion of patient enrollment in a Phase 3 trial for pirfenidone in treating pneumoconiosis. The company is also strategically planning to submit an IND application for hydronidone in MASH-associated liver fibrosis in 2026, allowing time to incorporate valuable data from previous trials. These developments, alongside the company’s engagement with China’s NMPA for priority review, position Gyre well for future growth and potential market approvals.
In another report released on November 3, Noble Financial also reiterated a Buy rating on the stock with a $20.00 price target.